ZYBERNO
Stock Report
Updated Aug 31, 2026

ENLIVEN THERAPEUTICS, INC. (ELVN)

Healthcare • NASDAQ

$57.86

Professional Investment Analysis

ZYBERNO SCORE
Is it a great business? Is it getting better?
18.0/100
POOR BUSINESS
ENLIVEN THERAPEUTICS, INC. (ELVN) scores 18/100 — concerning metrics indicating significant structural or financial risks.
📊 How is the Zyberno Score calculated? +
VALUATION SIGNAL
N/A (Requires more data)
Requires fair value calculation and current price data
💰 How is Margin of Safety calculated? +
📈 How is Brina Gap calculated? +

Critical Financial Health Indicators

Return on Equity (Profitability):CRITICAL (-18.5%)
Debt-to-Equity (Solvency Risk):EXCELLENT (0.00x)
Operating Margin (Operational Efficiency):CRITICAL (0.0%)
Return on Capital (Capital Efficiency):CRITICAL (-6,395.5%)
📊 Valuation Trilogy
Three interconnected metrics for complete valuation analysis
Click any metric for full methodology and detailed analysis
Zyberno's Verdict

ENLIVEN THERAPEUTICS, INC. (ELVN) stock report — Zyberno Score 18/100 (POOR BUSINESS). Full financial analysis on Zyberno.

Over the trailing twelve months, ELVN generated -$65.55M in Owner Earnings. Capital was deployed as follows: $138.00K invested in capital expenditures. Reinvestment rate: 0.2%.

DIVISION I: EXECUTIVE SUMMARY
A. Market Valuation

Market Price & Capitalization (2)

Current Price:57.86
Market Cap:$3.83B

Valuation Multiples (2)

P/B Ratio:4.28x
Peg Ratio:-999.00x

Enterprise Metrics (1)

Enterprise Value:$2.93B

Price Action & Momentum (3)

Momentum Percentile:95 / 100
% of 52-Week High:92.8%
B. Profitability Assessment

Return Metrics (5)

ROA:-18.1%
Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-9.7%

Margin Analysis (1)

Ebitda Margin:0.0%

Yield Metrics (2)

Earnings Yield:-$2.83
Dividend Yield:0.0%
C. Log-Linear Regression Growth Trends

Earnings Surprise (SUE) (3)

EPS Surprise vs Expected:-56.5%
Latest Earnings Filed:2026-08-05
D. Financial Stability

Liquidity Ratios (3)

Current Ratio:64.07x
Quick Ratio:64.07x
Cash Ratio:63.22x

Leverage Analysis (3)

Debt To Equity Ttm:0.00x
Debt-to-Equity Ratio:0.00x
Debt To Ebitda:-999.00x

Coverage Ratios (1)

Times Interest Earned:-999.00

Capital Structure (4)

Working Capital:893,178,000.00
Cash And Cash Equivalents:895,200,000.00
Long Term Debt:$913.00K
Net Debt:-$893.69M
DIVISION II: FINANCIAL STATEMENTS ANALYSIS
A. Income Statement Analysis

Revenue Components (2)

$0.00
Cost Of Revenue Ttm:$0.00

Profitability Breakdown (2)

$0.00-$124.41M

Bottom Line Performance (3)

-$105.93M
Income Before Tax:$0.00
Ebitda Ttm:-124,247,000.00

Operating Expenses (5)

Operating Expenses:124,413,000.00
R And D Expense:89,153,000.00
Sga Expense:35,260,000.00
Income Tax Expense:$232.00K
Interest Expense:0.00

Expense Ratios (1)

Ebitda Margin:0.0%
B. Balance Sheet Analysis

Asset Composition (5)

Total Assets:$910.22M
Current Assets:$907.34M
Ppe Net:140,000.00
Goodwill:0.00
Intangible Assets:$0.00

Liability Structure (4)

Total Liabilities:15,074,000.00
Current Liabilities:14,161,000.00
Long Term Debt:$913.00K
Short Term Debt:$597.00K

Equity & Capital (3)

Equity:$895.15M
Retained Earnings:-$403.28M
Common Stock:200,000,000.00

Working Capital Items (3)

Accounts Receivable:0.00
Inventory:0.00
Accounts Payable:371,000.00

Special Items (2)

Contract Liabilities:0.00
Stock Based Compensation:13,915,000.00
C. Cash Flow Analysis

Operating Activities (2)

-$65.47M-$65.60M

Investment Activities (2)

Investing Cash Flow:$42.53M
Capital Expenditures Ttm:138,000.00

Financing Activities (3)

Financing Cash Flow:$10.05M
Dividends Paid Ttm:0.00
Stock Repurchase:0.00

Capital Transactions (3)

Common Stock Issuance:0.00
Long Term Debt Issuance:$0.00
Long Term Debt Repayments:$0.00

Non-Cash Items (1)

Depreciation Amortization Ttm:166,000.00
DIVISION III: OPERATIONAL METRICS
A. Per Share Analysis

Earnings Per Share (3)

EPS (Basic TTM):-1.64
-$1.64
Earnings Per Share Ttm:-$1.60

Revenue & Cash Per Share (1)

Operating Cash Flow Per Share:-$1.06

Book Value & Capital (2)

Book Value Per Share:$13.53
Cash Per Share:13.53

Dividend Policy (1)

Dividend Payout Ratio:-999.00x
B. Operational Efficiency

Asset Utilization (1)

Working Capital Turnover Ttm:-999.00x

Receivables Management (2)

Receivables Turnover Ttm:-999.00x
Days Sales Outstanding Ttm:-999.00

Inventory Management (2)

Inventory Turnover Ttm:-999.00x
Days Inventory Outstanding Ttm:-999.00

Payables & Cash Cycle (2)

Days Payable Outstanding:-999.00
Cash Conversion Cycle:-999.00
C. Quality & Risk Metrics

Financial Quality Scores (2)

Financial Strength Score:100.00
Quality Score:30.00

Market Metrics (2)

Beta:0.00x
Volatility Category:unknown
DIVISION IV: INVESTMENT ANALYSIS
A. Value Investment Framework

Owner Earnings Analysis (1)

-$65.55M

Damodaran Growth Analysis (2)

Reinvestment Rate:0.2%
Fundamental Growth Rate (g):-9.7%
B. Log-Linear Regression Growth Analysis

Other Growth Rates (1)

Book Value Growth Rate (Linear):64.8%
C. Company Profile & Context

Corporate Information (6)

Symbol:ELVN
Company Name:ENLIVEN THERAPEUTICS, INC.
Sector:Healthcare
Industry:Pharmaceuticals
Exchange:NASDAQ
Country:United States

Market Classification (3)

Market Cap Category:N/A
Price Category:high
Volume Category:N/A

Share Structure (3)

Shares Outstanding:66.17M
Shares Outstanding Basic:66.17M
Shares Outstanding Diluted:66.17M

Data Processing Info (3)

Processing Version:v3.0
Last Updated:2026-08-31 05:11:28 UTC
Data Timestamp:2026-08-31T05:11:28.582107
Scroll to Top